DE 
EN 
ES 
A research-focused comparison of Melanotan II and PT-141, covering melanocortin receptor selectivity, evidence, safety signals and regulatory status.
Yohimbine is one of the best-characterised alpha-2 adrenergic receptor antagonists — a compound that for decades has served pharmacology as a tool for studying the noradrenergic regulation of the nervous system and of lipid metabolism. The name “yohimbine” itself, however, has attracted considerable confusion. Pure yohimbine hydrochloride is mistaken for yohimbe bark extract, and the regulatory status of the substance in the European Union is often described imprecisely. This article sets out three things that matter to anyone looking for reliable knowledge rather than a promise: the pharmacology of the alpha-2 receptor, the difference between yohimbine HCl and yohimbe extract, and what yohimbine is from the perspective of EU food law and the research-reagent framework.
Yohimbine is an indole alkaloid and an antagonist of alpha-2 adrenergic receptors — membrane proteins that inhibit the release of noradrenaline and limit lipolysis in adipose tissue. Isolated from the bark of Pausinystalia johimbe, it serves in pharmacology as a tool for studying adrenergic regulation. Yohimbine hydrochloride is a defined chemical compound of known purity, distinct from bark extract of variable composition. A chemical reagent intended exclusively for laboratory research (Research Use Only).
⚠️ The following article is educational in nature and provides a review of the published scientific literature on alpha-2 receptor pharmacology. The studies described were conducted in animal models, in vitro or in clinical settings — this is indicated for each study. The material does not constitute medical, pharmaceutical or dietary advice, does not describe any food use and is not an encouragement for human use of the substance. Yohimbine is discussed solely as a substance under investigation and as a research reagent.
Yohimbine belongs to the family of monoterpenoid indole alkaloids — compounds with an elaborate ring structure, structurally related to reserpine. It occurs naturally in the bark of the West African tree Pausinystalia johimbe (also written Pausinystalia yohimbe in older literature). The bark of this plant was used in the traditions of West and Central Africa, mainly as a stimulant and aphrodisiac — an ethnobotanical fact, not an effect confirmed in the sense of modern pharmacology.
For the researcher, however, what matters is not the tree but the defined molecule. The form used in the laboratory is yohimbine hydrochloride (the hydrochloric acid salt, CAS 65-19-0). Yohimbine base has the molecular formula C21H26N2O3 and a molar mass of approximately 354.4 g/mol; the hydrochloride form improves solubility and stability, giving a salt with a reproducible content of the active substance per unit mass. It is precisely this reproducibility that distinguishes a defined compound from plant raw material.
In modern pharmacology, yohimbine gained attention as an alpha-2 adrenergic receptor antagonist. Historically it was registered in some countries as a medicine for erectile dysfunction, but in this role it has largely been replaced by phosphodiesterase type 5 inhibitors (for example sildenafil). In the experimental literature, yohimbine functions above all as a pharmacological probe — a tool that makes it possible to selectively “switch off” the alpha-2 receptor and observe what happens to the processes that depend on it (Goldberg and Robertson, 1983; Tam et al., 2001).
The broader context of metabolic modulators and compounds that affect performance is covered in the review article on SARMs and selective androgen receptor modulators.
To understand yohimbine, one has to understand what the alpha-2 receptor is and what function it serves in the noradrenergic system. Adrenergic receptors are proteins of the G protein-coupled receptor (GPCR) family that respond to noradrenaline and adrenaline. They fall into two main classes — alpha and beta — which are divided further into subtypes. The alpha-2 receptor is coupled to the Gi/Go protein, which inhibits the enzyme adenylyl cyclase. Stimulation of the alpha-2 receptor therefore lowers the intracellular concentration of the second messenger cAMP — which in turn dampens the processes that cAMP normally drives.
Of particular importance is the location of some alpha-2 receptors on the terminals of noradrenergic neurons themselves — as so-called presynaptic autoreceptors. They form a negative feedback loop: when a large amount of noradrenaline is present in the synaptic cleft, some of the molecules bind the presynaptic alpha-2 receptor, which inhibits further noradrenaline release. The receptor acts as a thermostat — it tells the neuron “that’s enough” and quietens the signal.
Yohimbine binds this receptor and blocks it without stimulating it (it acts as an antagonist, not an agonist). Blocking the presynaptic autoreceptor removes the inhibitory mechanism, so the neuron releases more noradrenaline and noradrenergic tone rises. This is the pharmacological explanation of why the clinical literature has linked alpha-2 antagonism with an increase in plasma noradrenaline, an accelerated heart rate and a rise in blood pressure (Tam et al., 2001). The same relationship underlies the observation that yohimbine has been used experimentally as a pharmacological model for inducing anxiety — increased noradrenaline release heightens central nervous system arousal.
The alpha-2 receptor is not uniform. Three subtypes are distinguished — alpha-2A, alpha-2B and alpha-2C — encoded by separate genes and distributed across different tissues:
Yohimbine is an antagonist with relatively low selectivity for these subtypes — it blocks them broadly and, at higher concentrations, also shows affinity for other receptors (including 5-HT1A and, to a lesser extent, alpha-1). The review by Tam et al. (2001) discusses this selectivity profile as important for interpreting results: an observed effect does not always stem from “pure” alpha-2 antagonism, which has to be taken into account when designing an experiment. This is why comparative studies set yohimbine alongside other alpha-2 ligands with different subtype selectivity.
Alpha-2 receptors are found not only on neurons. Fat cells (adipocytes) carry two opposing types of adrenergic receptor on their surface. Beta receptors (β1, β2, β3), coupled to the Gs protein, raise cAMP levels and activate hormone-sensitive lipase — the enzyme that breaks down triglycerides into glycerol and free fatty acids. Alpha-2 receptors, coupled to Gi, act in the opposite direction: they lower cAMP and suppress this breakdown. In other words, within the same cell, alpha-2 acts as a brake on the “accelerator” of the beta-adrenergic signal.
The ratio of beta to alpha-2 receptors varies between regions of the body, as described in the extensive review by Lafontan and Berlan (1993). Where alpha-2 receptors predominate, the suppression of lipolysis is stronger — and it is this pharmacology that explains why certain adipose tissue depots respond to metabolic signals differently from others. An alpha-2 antagonist such as yohimbine removes this local inhibition at the receptor level. The framing is worth stressing: this is a description of a pharmacological mechanism studied in models, not information about the intended use of yohimbine or a promise of any effect in humans.
For the researcher this distinction is fundamental, yet in popular descriptions it is most often lost. “Yohimbine HCl” and “yohimbe” are not synonyms — they are two different categories of material.
Yohimbine hydrochloride (yohimbine HCl) is a single, defined chemical compound. It has one molecular formula, one molar mass and — once purified — a known, measurable purity. A batch with purity confirmed by HPLC contains the same amount of active substance per unit mass regardless of when and where it was produced. This is a precondition for reproducible concentration–response studies.
Yohimbe (bark extract) is a plant raw material. The bark of Pausinystalia johimbe contains yohimbine, but it makes up only part of a complex pool of indole alkaloids. It is accompanied by, among others, rauwolscine (alpha-yohimbine), corynanthine and several dozen minor compounds — in proportions that depend on the tree, the region, the time of harvest and the extraction method. The yohimbine content of the bark itself is low and variable, and label declarations on products can differ from reality. Independent analyses of yohimbe products available on the market have shown considerable differences between declared and measured yohimbine content — from trace amounts to values several times higher than declared (Cohen et al., 2023).
The consequences of this difference are concrete. First, variable content means that two portions of extract of the same mass may contain substantially different amounts of yohimbine — which makes it impossible to define a concentration–response relationship. Second, the accompanying alkaloids are not pharmacologically inert: rauwolscine is an alpha-2 antagonist in its own right with a different subtype selectivity, and corynanthine shifts the profile towards the alpha-1 receptor. The extract is therefore a mixture of ligands with partly opposing actions, in which it is difficult to attribute an observed effect to a specific molecule. Third, plant raw material carries a risk of contamination and batch-to-batch variability, which itself becomes a confounding variable.
For the researcher, the conclusion is unambiguous: alpha-2 receptor pharmacology is studied with a pure, characterised compound of confirmed identity and purity, not with an extract of undefined composition. The table below sets out the main alkaloids of yohimbe bark and their relationship to yohimbine.
| Alkaloid | Relationship to yohimbine | Pharmacological profile (simplified) |
|---|---|---|
| Yohimbine | The main alkaloid described | Alpha-2 receptor antagonist |
| Rauwolscine (alpha-yohimbine) | Diastereoisomer of yohimbine | Alpha-2 antagonist with a different subtype selectivity |
| Corynanthine | Diastereoisomer | Preferential affinity for the alpha-1 receptor |
| Minor alkaloids (corynantheine and others) | Trace constituents of the bark | Variable, mostly poorly characterised |
The content of each of these compounds in an extract varies — and this is exactly the uncertainty that working with yohimbine hydrochloride of known purity eliminates.
The overview below describes what has been reported in published research on the pharmacology of alpha-2 antagonism. It is not a description of the intended use of yohimbine or a promise of an effect — it is a summary of observations from experimental and clinical models, presented within a research framework.
In the pharmacological literature, alpha-2 receptor antagonism has been studied, among other things, for its effect on lipid mobilisation. Work by Galitzky et al. (1988) on isolated human adipocytes in vitro and in healthy volunteers showed that alpha-2 receptor blockade was associated with increased release of glycerol — a marker of triglyceride breakdown — particularly in adipocytes from depots rich in these receptors. In vitro conditions do not fully reflect whole-body physiology, as the authors themselves note.
The extensive review by Lafontan and Berlan (1993) describes the mechanism by which alpha-2 receptors limit lipolysis and by which their antagonists remove this limitation — as a fact of the adrenergic regulation of metabolism, not as an indication. In Ostojic’s (2006) clinical study, a double-blind, placebo-controlled trial in professional footballers, a significant change in percentage body fat with no change in body weight was recorded in the yohimbine arm; the author describes this as an observation on body composition in healthy, active men. All of these observations are cited within a research framework — as what was reported in specific models, not as an expected result for the reader.
Pharmacology adds important context here: insulin inhibits lipolysis independently of adrenergic receptors. This means that nutritional status and insulin concentration are variables that, in the literature, determined the outcome of experiments with alpha-2 antagonists — ignoring them leads to results that are difficult to reproduce. For anyone designing a study, this is information about controlling variables, not guidance on use.
Historically, yohimbine was studied in the context of erectile dysfunction, which is linked to its effect on noradrenergic tone and blood vessels. Among the better-documented studies is the work by Kernohan et al. (2005) on an oral combination of yohimbine with L-arginine (a preparation designated NMI 861) — a pharmacokinetic and pharmacodynamic study in healthy men that also included an interaction analysis. This work documents the pharmacokinetic profile of oral yohimbine combined with L-arginine and remains within the framework of a clinical study, not a therapeutic recommendation. More broadly, the review by Tam et al. (2001) discusses the data on the use of yohimbine in this area, together with their limitations.
The increased release of noradrenaline after blockade of presynaptic alpha-2 receptors translates into measurable cardiovascular parameters. The review by Tam et al. (2001) brings together observations indicating that yohimbine raised plasma noradrenaline levels, accelerated heart rate and increased blood pressure. These effects are pharmacologically consistent with the mechanism described earlier and, at the same time, represent the main area of risk, discussed below.
Yohimbine is a pharmacologically active substance with a pronounced profile of action on the central and peripheral nervous systems — it is far from a “mild” compound. The review by Tam et al. (2001), as a clinical reference, documents the spectrum of adverse effects reported in the literature:
Two aspects deserve emphasis in a research context. First, yohimbine is described as a compound with a narrow window between the dose that produces a pharmacological effect and the dose that provokes marked adverse effects — which calls for careful monitoring of cardiovascular parameters in any model involving it. Second, there is considerable inter-individual variability in response, linked among other factors to the metabolism of yohimbine by the CYP2D6 isoenzyme; poor metabolisers may reach a higher exposure from the same amount of substance. A risk of serious interactions has also been noted, including with monoamine oxidase (MAO) inhibitors. This information is given as a description of the profile of a substance under investigation, not as guidance on use in humans.
Regulatory status is the third area in which “yohimbine” is often described incorrectly — and at the same time the reason why the research-reagent framework is appropriate here.
At EU level, the European Food Safety Authority (EFSA) published a scientific opinion in 2013 on the safety of use of yohimbe (Pausinystalia johimbe) in food. The EFSA Panel concluded that the available data do not allow the safety of yohimbe bark and its preparations to be established, pointing to reported adverse effects on the cardiovascular and central nervous systems (EFSA ANS Panel, 2013). No health claims have been authorised for yohimbine as a food ingredient.
At national level the picture is mixed, but in many EU member states yohimbe and yohimbine are not permitted as ingredients of food supplements. In some countries yohimbine is treated as a medicinal substance available only on prescription (for example, in Germany and the United Kingdom yohimbine is listed among substances prescribed by a doctor), while in others yohimbe bark and its preparations have been explicitly excluded from use in foods and supplements (for example in France). There is no harmonised, EU-wide positive list permitting yohimbine as a supplement ingredient — which in practice means that, as a food ingredient, it remains prohibited in many jurisdictions.
A simple, clarifying conclusion follows from this patchwork. Yohimbine is a defined, pharmacologically active substance that does not function on the EU market as a legal ingredient of dietary supplements or as a food product. The framework within which yohimbine is described and offered in line with its intended purpose is that of a research reagent (Research Use Only) — a substance for laboratory use, not intended for human consumption. The regulatory reality here is not a restriction to be circumvented “on the side” — it is the same line drawn by the reagent status: material for research, not for consumption.
In laboratory applications, yohimbine is supplied as yohimbine hydrochloride of confirmed identity and purity. For reproducible experiments, the relevant parameters are the same ones that distinguish a defined compound from an extract: confirmation of the identity of the molecule, determination of purity by a chromatographic method (HPLC), and a certificate of analysis (COA) supplied with the batch. The certificate makes it possible to relate an observed effect to a known amount of a defined substance rather than to an unspecified mixture of alkaloids.
Researchers working on alpha-2 receptor pharmacology will find yohimbine in the One-Peptides research catalogue as a dedicated reagent category. The detailed parameters of an individual batch — form, declared purity and scope of documentation — are described on the yohimbine hydrochloride product page for the research reagent.
What is yohimbine? Yohimbine is an indole alkaloid isolated from the bark of the Pausinystalia johimbe tree. In pharmacology it is described as an alpha-2 adrenergic receptor antagonist and is used as a research probe for studying noradrenergic regulation. In the One-Peptides catalogue it is available solely as a research reagent (Research Use Only).
How does yohimbine HCl differ from yohimbine? Yohimbine HCl is yohimbine hydrochloride — the hydrochloric acid salt of yohimbine base. The salt form improves solubility and stability and provides material with a reproducible content of the active substance per unit mass. “Yohimbine” and “yohimbine HCl” refer to the same molecule; the term “HCl” specifies the chemical form used in the laboratory.
Yohimbine vs yohimbe — are they the same thing? No. Yohimbine is a single, defined chemical compound. Yohimbe is a plant raw material (bark) containing yohimbine together with many other alkaloids — rauwolscine, corynanthine and minor compounds — in variable proportions. Two bark extracts of the same mass may contain substantially different amounts of yohimbine, which is why research uses pure yohimbine hydrochloride rather than extract.
How does yohimbine act on the alpha-2 receptor? Yohimbine binds the alpha-2 receptor and blocks it as an antagonist, without stimulating it. Blocking presynaptic alpha-2 autoreceptors removes the negative feedback mechanism, so neurons release more noradrenaline. At the level of the adipocyte, alpha-2 blockade removes the inhibition of cAMP-dependent lipolysis — described in research as a pharmacological fact, not as an effect guaranteed in humans.
What does it mean that yohimbine is an alpha-2 antagonist? An antagonist is a compound that binds a receptor but does not activate it — instead, it blocks access for the natural messenger (here: noradrenaline). By blocking the alpha-2 receptor, yohimbine “switches off” its inhibitory action. Hence its role as a pharmacological probe: it makes it possible to observe what happens when the alpha-2 receptor stops transmitting its signal.
Why does yohimbine increase noradrenaline release? Because some alpha-2 receptors act as autoreceptors on the terminals of noradrenergic neurons and normally inhibit further noradrenaline release. Blockade of these receptors by yohimbine removes the brake — which is why the clinical literature has linked alpha-2 antagonism with increased noradrenaline levels, an accelerated heart rate and raised blood pressure (Tam et al., 2001).
What is the legal status of yohimbine and yohimbe in the European Union? In many EU member states, yohimbe and yohimbine are not permitted as ingredients of food supplements. In its 2013 opinion, EFSA concluded that the available data do not allow the safety of yohimbe bark in food to be established. In some countries yohimbine is available only on prescription. As a food ingredient it therefore remains prohibited in many jurisdictions; the appropriate framework is research-reagent status.
Is yohimbine a steroid or a SARM? No. Yohimbine is an indole alkaloid acting on alpha-2 adrenergic receptors — it is not a steroid, nor is it a selective androgen receptor modulator (SARM). It belongs to an entirely different class of compounds from hormonal modulators and acts on a different receptor system.
What has been reported in research on yohimbine and lipolysis? In in vitro models on human adipocytes and in review articles, alpha-2 receptor blockade has been described as removing the inhibition of lipolysis and as being associated with increased glycerol release (Galitzky et al., 1988; Lafontan and Berlan, 1993). These are observations from receptor pharmacology, cited within a research framework, not information about the intended use of yohimbine or an expected effect for the reader.
Is yohimbine on the WADA list? At the time of publication, yohimbine is not on the World Anti-Doping Agency (WADA) Prohibited List. These lists are updated annually, however, so the current status should always be checked directly in the WADA database.
How does yohimbine differ from rauwolscine? Rauwolscine (alpha-yohimbine) is a diastereoisomer of yohimbine — a compound with the same formula but a different spatial configuration. It is also an alpha-2 antagonist, but it has a different selectivity profile across the receptor subtypes. Rauwolscine is one of the alkaloids that accompany yohimbine in yohimbe bark, which further explains why the extract is harder to define pharmacologically than the pure compound.
What is yohimbine as a research reagent? It is yohimbine hydrochloride of confirmed identity and purity (HPLC), with a certificate of analysis (COA) for the batch, intended exclusively for laboratory use. It is not a medicine, a dietary supplement or a product for human consumption.
ℹ️ Global disclaimer Yohimbine offered by One-Peptides is a chemical reagent intended exclusively for laboratory and scientific research (Research Use Only). It is not a medicine, a dietary supplement, a food product or a product intended for human consumption. The information in this article is educational in nature and provides a review of the published scientific literature on alpha-2 receptor pharmacology; it does not constitute medical, pharmaceutical or dietary advice, does not describe any food use and is not an encouragement for human use of the substance. Yohimbine is a pharmacologically active substance with a pronounced cardiovascular and central profile — in a research context it requires careful monitoring of parameters.
A research-focused comparison of Melanotan II and PT-141, covering melanocortin receptor selectivity, evidence, safety signals and regulatory status.
A research comparison of MK-677 and ipamorelin, focusing on GHS-R1a signaling, selectivity, administration route, human evidence and WADA status.
We offer a wide selection of peptides tailored to a range of laboratory analytical needs.
Every batch is tested for identity and purity (HPLC, MS) and comes with a certificate of analysis.
We invest in analytical testing and full batch documentation for every product.
Unsere zahlreichen positiven Bewertungen spiegeln die Zufriedenheit unserer Kunden wider, die immer wieder zurückkommen.
Melden Sie sich für den Newsletter an!
Erhalten Sie 10 % Rabatt auf Ihren ersten Kauf
One-Peptides.com
Informationen
© 2026 ONE-PEPTIDES.COM